Wednesday, Sept. 4, 2019
Registration and Breakfast
Opening RemarksAlessandra Cesano, MD, PhD – ESSA Pharma Inc.
Session I: Germline, Somatic Genetics, and Epigenetics of Immune Landscapes
Davide Bedognetti, MD, PhD – Sidra Medical and Research CenterJosue Samayoa, PhD – AbbVie
Germline Genetic Variation Predicts Immune Signatures in the Cancer Genome AtlasElad Ziv, MD – University of California San Francisco
Link Between Metastatic Genetic Heterogeneity and the Immune Contexture in Colorectal CancerJérôme Galon, PhD – INSERM, Sorbonne Universites Paris
Germline Biomarkers of Metastatic Melanoma Immunotherapy: Pilot Results of International ConsortiaTomas Kirchhoff, PhD – New York University School of Medicine
Mutation Drivers of Immunological Responses to CancerEduard Porta, PhD – Barcelona Supercomputing Centre
Session II: Transcriptional Patterns of Distinct Immune Landscapes
Yana Najjar, MD – University of Pittsburgh Hua Yu, PhD – City of Hope
STAT3: Targeting Master Regulator of Immune Checkpoints Marcin Kortylewski, PhD – City of Hope
Immune Gene Expression as a Discovery Tool for Actionable Immunotherapy Resistance MechanismsRandy F. Sweis, MD – UChicago Medicine
Transcriptional Signatures of Immune Surveillance and a Favorable Tumor Immune Micro-environmentYvonee Saenger, MD – Columbia University/ New York Presbyterian
Session III: Therapeutic Interventions to Modify the Cancer Microenvironment and Related Experimental Systems for Validation
10:55 a.m.–12:15 p.m.
Rongze Lu, PhD – AbbvieSarah Warren, PhD – NanoString Technologies, Inc.
Macrophage Immune Checkpoint CD47 is a Novel Therapeutic TargetSamuel Henry Cheshier, MD, PhD – University of Utah
Working Group Breakout Sessions
Working Group 1:
Working Group 2:
Working Group Presentations
Working Group 1: Germline, Somatic Genetics, and Epigenetics of Immune LandscapesDavide Bedognetti, MD, PhD – Sidra MedicalJosue Samayoa, PhD – AbbVie
Working Group 2: Transcriptional Patterns of Distinct Immune LandscapesYana Najjar, MD – University of Pittsburgh Hua Yu, PhD – City of Hope
Thursday, Sept. 5, 2019
Opening RemarksFranco Marincola, MD – Refuge Biotechnologies
Session I: State of the Field of Adoptive Cellular Therapy
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
IntroductionAlessandra Cesano, MD, PhD – ESSA Pharma Inc.Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
T cells Recognizing Antigen Through Native or Chimeric ReceptorsHelen E. Heslop, MD – Baylor College of Medicine
Session II: External Circumstantial Factors
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
T cell-intrinsic and -extrinsic Determinants of Response to CAR T cell TherapyJ. Joseph Melenhorst, PhD – University of Pennsylvania
Effects of Co-Morbidities and Concomitant Medications on Immunotherapy Efficacy and SafetyMichael N. Liebman, PhD – IPQ Analytics, LLC
Learning to Harness Cancer-Curing Poop as a Group: Collaborative Microbiome Research and Beyond at the Parker Institute for Cancer Immunotherapy Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
Microbiome: Methods and New Technologies for Sample Collection and Assay StandardizationTessa Andermann, MD, MPH – Stanford University
Session III: Emerging Ideas and New Concepts
11:55 a.m.–12:55 p.m.
Francesco M. Marincola, MD – Refuge Biotechnologies, Inc.Kyung-Ho Roh, PhD – University of Alabama in Huntsville
Detection and Activation of CAR-T Cells Using Standardized ModelsKyung-Ho Roh, PhD – University of Alabama in Huntsville
Conditional Regulation of CAR T Stanley Qi, PhD – Stanford University
T cell ReprogrammingLuca Gattinoni, MD – National Cancer Institute
Cancer Immune Responsiveness Workshop Adjourns
Schedule is subject to change.
This program has been supported, in part, by grants from Celgene Corporation, NanoString Technologies, Inc., Pfizer, Inc., and Refuge Biotechnologies.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com